Dr Reddy’s launches antibiotic drug in US

Tags: News
Indian drug maker Dr Reddy’s has launched a generic and low priced version of the brand Avelox which is under marketing license with Merck. For the US market, the brand has total sales of $195 million at the end of one year in December 2013, estimates IMS Health.

The tablets which have Moxifloxacin Hydrochloride as active ingredient would come in 400 mg form. “Presenty, the competition for the drug is low, with only two other generic players, that is Teva and Aurobindo Pharma with approvals. We expect Dr Reddy’s to post sales of $20 million and net profit $5 million for this drug,” said Sarabjit Kour Nangra, senior vice-president (research, pharma) — Angel Broking.

The anti-infective (bacterial infections) drug contains moxifloxacin which is associated with an increased risk of tendinitis and tendon rupture in all ages. This risk is aggravated in patients above 60 years of age and taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. While Bayer Healthcare manufactures the branded drug, Merck distributes it.

trushnaudgirkar

@mydigitalfc.com

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • With RBI’s role diluted, we are moving closer towards a super regulator

    The government and the Reserve Bank of India (RBI) have signed a monetary policy framework agreement last month under which RBI will be committed to b

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Roopen Roy

The making of a digital Bharat

Exactly 20 years ago, Nicholas Negroponte of MIT Media Labs ...

Rajgopal Nidamboor

The eternal radiance of our being

We sense, we sight, we smell, we touch, we hear, ...

Shona Adhikari

Art world celebrates two ‘new’ Cezannes

The focus moves once more to post-impressionist Paul Cezanne, who ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture